ABSTRACT
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases with a variable clinical course and outcome. It affects approximately 1 in 1000 children in the United Kingdom, with 58 prevalent cases of JIA per 100,000 15-to 24-year-olds (1). These children have a significant risk of long-term morbidity, with at least one-third of children continuing to have active inflammatory disease into adulthood (2-4). Up to 60% of all patients continue to have some limitation of their activities of daily living (3-6).
